The Prostate SPORE Developmental Research Program operates under the direction of the Administrative Core. The SPORE sets aside $150,000 each year (plus Institutional support) to fund 4-5 feasibility projects to generate data that will enable the investigator to apply for extramural funds. In January of each year a request for pilot projects is sent out to all members of the Cancer Centers at Northwestern University and the University of Chicago. There is an established process for peer review of pilot projects by an ad hoc review committee. The SPORE Executive Committee takes priority scores and makes the final funding decision. The process is flexible, in that pilot projects can be elevated to replace full SPORE projects and pilot projects can be terminated if progress is not satisfactory. For example, Project 4 (PI: Bergan and Catalona) and Project 3 (PI: Weichselbaum and Stadler) were both pilot projects that were elevated to full project status based on significant progress made. And Project 2 (PI: Crawford, Gapstur and Lee) has also been elevated from a pilot project. Additionally, an investigator may submit a pilot project at any time to the SPORE Director. It is reviewed by the ad hoc committee and if favorably reviewed and if adequate funds exist, it may receive funding. Therefore, the Developmental Research Program enables the Prostate SPORE to expand investigator participation to bring more investigators into the field to maximize our research efforts on prostate cancer. A detailed description of pilot projects is described in Section XII of the application

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-M)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Northwestern University at Chicago
United States
Zip Code
Hung, Michelle E; Leonard, Joshua N (2016) A platform for actively loading cargo RNA to elucidate limiting steps in EV-mediated delivery. J Extracell Vesicles 5:31027
Ye, Cong; Geng, Zhe; Dominguez, Donye et al. (2016) Targeting Ornithine Decarboxylase by α-Difluoromethylornithine Inhibits Tumor Growth by Impairing Myeloid-Derived Suppressor Cells. J Immunol 196:915-23
Kregel, Steven; Chen, James L; Tom, Westin et al. (2016) Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer. Oncotarget 7:26259-74
Nyame, Yaw A; Murphy, Adam B; Bowen, Diana K et al. (2016) Associations Between Serum Vitamin D and Adverse Pathology in Men Undergoing Radical Prostatectomy. J Clin Oncol 34:1345-9
Pascal, Laura E; Masoodi, Khalid Z; O'Malley, Katherine J et al. (2015) 5α-Reductase inhibition coupled with short off cycles increases survival in the LNCaP xenograft prostate tumor model on intermittent androgen deprivation therapy. J Urol 193:1388-93
Lindholm, Paul F; Sivapurapu, Neela; Jovanovic, Borko et al. (2015) Monocyte-Induced Prostate Cancer Cell Invasion is Mediated by Chemokine ligand 2 and Nuclear Factor-κB Activity. J Clin Cell Immunol 6:
Zhang, Ali; Zhao, Jonathan C; Kim, Jung et al. (2015) LncRNA HOTAIR Enhances the Androgen-Receptor-Mediated Transcriptional Program and Drives Castration-Resistant Prostate Cancer. Cell Rep 13:209-21
Hung, Michelle E; Leonard, Joshua N (2015) Stabilization of exosome-targeting peptides via engineered glycosylation. J Biol Chem 290:8166-72
Loeb, Stacy; Sanda, Martin G; Broyles, Dennis L et al. (2015) The prostate health index selectively identifies clinically significant prostate cancer. J Urol 193:1163-9
Jovanovic, Borko D; Subramanian, Hariharan; Helenowski, Irene B et al. (2015) Clinical Trial Laboratory Data Nested With in Subject: Components of Variance, Sample Size and Cost. Biom Biostat Int J 2:

Showing the most recent 10 out of 193 publications